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ABSTRACT
Mothers against decapentaplegic homolog 7 (SMAD7) inhibits the transforming 
growth factor-β (TGF-β) signaling pathway, which regulates carcinogenesis and 
cancer progression. A number of studies have reported that SMAD7 polymorphisms 
(rs4464148, rs4939827, and rs12953717) are associated with colorectal cancer (CRC) 
risk, but the results from these studies remain conflicting. To determine a more precise 
estimation of the relationship between SMAD7 and CRC, we undertook a large-scale 
meta-analysis of 63 studies, which included a total of 187,181 subjects (86,585 cases 
and 100,596 controls). The results of our meta-analysis revealed that the C allele 
of rs4464148 [CC vs. TT+TC, odds ratio (OR) =1.23, 95% confidence interval (CI): 
1.14–1.33, P < 0.01], the T allele of rs4939827 [TT vs. CC+TC, odds ratio OR=1.15, 
95%CI:1.07–1.22, P < 0.01] and the T allele of rs12953717 [TT vs. CC+TC, OR 
=1.22, 95%CI:1.16–1.29, P < 0.01] were all associated with the increased CRC risk. 
Subgroup analysis according to ethnicity showed rs4464148 and rs12953717 were 
associated with the risk of CRC in both Caucasians and Asians, whereas rs4939827 
was a risk polymorphism for CRC specifically in Caucasians. In summary, this large-
scale meta-analysis indicated that SMAD7 polymorphisms (rs4464148, rs4939827, 
and rs12953717) correlate with CRC.
INTRODUCTION
Cancer is caused by the dysfunction of intricate 
signaling pathways, leading to abnormal growth, 
metastasis, and many other events [1]. The transforming 
growth factor β (TGF-β) signaling pathway is one of 
major tumor-regulatory pathways, exerting critical tumor-
suppressive functions in the early stages of tumorigenesis 
[2, 3]. When TGF-β signaling is activated, downstream 
SMAD2 and SMAD3 proteins are phosphorylated, 
forming a complex with SMAD4 and then translocating 
to the nucleus to turn on and off the transcription of a 
wide range of target genes [4, 5]. SMAD7 inhibits TGF-β 
signaling by preventing the formation of the SMAD2/
SMAD4 complex [6]. It also interacts with activated 
TGF-β type I receptor and blocks the phosphorylation and 
activation of SMAD2 [6].
SMAD7 has also been reported to affect 
tumorigenesis via several other mechanisms. First, 
in FET-1 colon cancer cells, SMAD7 induces the 
expression of IκB, thereby repressing NF-κB activity 
[7]. Secondly, SMAD7 up-regulates MYC expression and 
WNT signaling via interactions with β-catenin in breast 
cancer [8] and hepatocellular carcinoma [9]. In addition, 
SMAD7 inhibits ERK1/2, JNK1/2, and p38 MAPKs 
under some circumstances related with tumorigenesis, 
such as erythroid differentiation [10] and chondrocyte 
differentiation [11].
In 2007, Broderick and co-workers [12] conducted 
a genome-wide association study and identified three 
polymorphic variants in intron 3 of SMAD7 (rs4464148, 
rs4939827, and rs12953717). Furthermore, they found 
these SMAD7 polymorphisms were associated with 
CRC adenomas and carcinomas [12]. In a number of 
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other studies these SMAD7 polymorphisms have been 
associated with the risk of developing multiple cancers, 
including CRC [12–14], renal [15], and liver cancer [16]. 
However, other case-control studies have reported that 
these polymorphisms are not associated with cancer risk, 
in CRC [17–19], breast cancer [20], and lymphocytic 
leukemia [21]. These inconsistencies may be partially 
due to the relatively small sample sizes in each of these 
studies. Therefore, we performed a large-scale meta-
analysis of all eligible published studies to derive a more 
precise quantitative assessment of the association between 
SMAD7 polymorphisms and CRC risk.
RESULTS
Study selection and characteristics
Figure 1 is a flowchart explaining the study selection 
process. A total of 62 articles were initially retrieved from 
PubMed, Web of Science, EBSCO, and Embase electronic 
databases (last updated in June, 2016). Based on the search 
criteria, we excluded 33 ineligible records after carefully 
reviewing the full text and data, leaving 29 articles published 
between 2007 and 2016 for our quantitative meta-analysis.
The characteristics of SMAD7 polymorphisms 
(rs4464148, rs4939827, and rs12953717) in selected 
studies are shown in Table 1. There were 64 eligible studies 
from 29 articles analyzing the relationship of SMAD7 
polymorphisms and CRC risk. Among these studies, one 
was conducted on rs12953717, with a relatively small 
sample size (308 subjects) [22], which seems to have 
affected the results dramatically. Therefore, this study 
was excluded from analysis. Finally, 63 studies (published 
from 2007-2016) including 187,181 subjects (86,585 
cases and 100,596 controls) were used to estimate the risk 
of developing CRC with SMAD7 polymorphisms. Each 
subpopulation in the literature was treated as a separate 
study in our meta-analysis. Populations were divided 
into ethnic categories. The Newcastle-Ottawa Scale 
(NOS) was used for quality assessment [23] and all of the 
studies achieved moderately high quality scores above 6 
(Table 1). Among the included studies, 12 were conducted 
on rs4464148 (18,303 cases and 16,964 controls), 37 on 
rs4939827 (48,751 cases and 61,529 controls), and 14 on 
rs12953717 (19,531 cases and 22,103 controls).
Quantitative data synthesis
SMAD7 rs4464148 polymorphism
For each study, we investigated the association 
between the SMAD7 rs4464148 polymorphism and 
CRC risk, assuming different inheritance models. When 
all eligible studies were pooled into the meta-analysis, 
significant associations were found for the recessive 
genetic model (Table 2): CC vs. TC+TT (OR = 1.23; 95% 
Figure 1: Flowchart of the literature selection process.
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Table 1: Main characteristics of all case-control studies included in the meta-analysis
SNP Author Year Ethnicity Cancer 
type
Case Control HWE
(Control 
P value)
Study 
design
Genotyping 
method
Quality 
assessment
rs4464148 TT TC CC TT TC CC
Broderick et al. [12]
-A group
2007 Caucasian Colon 389 425 116 486 394 80 0.991 GWAS Illumina 8
-B group 2007 Caucasian Colon 2017 1952 472 1886 1617 346 0.982 Replication Allele-PCR 8
-C group 2007 Caucasian Colon 922 845 193 827 696 146 0.980 Replication Allele-PCR 8
-D group 2007 Caucasian Colon 422 408 99 171 137 27 0.952 Replication Allele-PCR 8
Thompson et al. [28] 2009 Caucasian Colon 269 231 61 342 324 53 0.045 Replication TaqMan 8
Curtin et al. [43] 2009 Caucasian Colon 503 472 95 535 423 89 0.678 Replication SNPlex 8
Pittman et al. [44] 2009 Caucasian Colon 1161 1107 264 1095 1277 235 0.996 Replication Allele-PCR 8
Ho et al. [35] 2011 Asian Colon 739 146 7 770 116 4 0.869 Replication Sequenom 7
Zhang et al. [38] 2014 Asian Colon 1 52 675 14 305 2957 0.999 Replication TaqMan 8
Kurlapska et al. [17] 2014 Caucasian Colon 1214 1228 400 84 96 33 0.523 Replication Sequenom 7
Damavand et al. [29] 2015 Caucasian Colon 138 78 37 113 101 20 0.700 Replication Taqman 7
Serrano-Fernandez 
et al. [45]
2015 Caucasian Colon 507 517 141 561 490 114 0.643 Replication Taqman 8
rs4939827 CC TC TT CC TC TT
Broderick et al. [12]
-A group
2007 Caucasian Colon 153 449 328 229 480 251 0.987 GWAS Illumina 8
-B group 2007 Caucasian Colon 852 2178 1392 845 1915 1084 0.989 Replication Allele-PCR 8
-C group 2007 Caucasian Colon 387 982 623 410 840 430 0.995 Replication Allele-PCR 8
-D group 2007 Caucasian Colon 194 477 292 76 171 96 0.923 Replication Allele-PCR 8
Tenesa et al. [14]
-Scotland(GWAS)
2008 Caucasian Colon 538 1521 926 706 1508 845 0.506 GWAS Illumina 8
-Japan 2008 Asian Colon 233 1582 2576 131 1028 2019 0.992 Replication TaqMan 8
-Canada 2008 Caucasian Colon 225 593 355 284 576 322 0.402 Replication TaqMan 8
-England 2008 Caucasian Colon 418 1120 694 546 1126 578 0.959 Replication TaqMan 8
-Spain 2008 Caucasian Colon 62 156 131 57 143 95 0,808 Replication TaqMan 8
-Germany 2008 Caucasian Colon 420 1071 659 541 1057 530 0.765 Replication TaqMan- 8
-Germany 2008 Caucasian Colon 289 617 412 378 704 358 0.403 Replication TaqMan 8
-Scotland 2008 Caucasian Colon 156 420 254 189 446 288 0.497 Replication TaqMan 8
-Israel 2008 Caucasian Colon 267 638 447 312 627 397 0.035 Replication TaqMan 8
Curtin et al. [43] 2009 Caucasian Colon 221 520 324 229 538 274 0.251 Replication SNPlex 8
Thompson et al. [28] 2009 Caucasian Colon 125 275 154 146 378 185 0.064 Replication TaqMan 8
Pittman et al. [44] 2009 Caucasian Colon 785 1250 497 725 1300 582 0.987 Replication Allele-PCR 8
Slattery et al. [46] 2010 Caucasian Colon 360 773 457 492 992 503 0.947 Replication TaqMan 8
Xiong et al. [33] 2010 Asian Colon 1370 677 77 1442 570 74 0.061 Replication T-ARMS-
PCR
8
von Hoslt et al. [47] 2010 Caucasian Colon 395 886 501 387 884 408 0.930 Replication deCode test 8
Kupfer et al. [48] 2010 African Colon 379 340 76 455 429 101 0.994 Replication Sequenom 7
Caucasian Colon 88 199 112 85 183 99 0.981 Replication Sequenom 7
Mates et al. [49] 2010 Caucasian Colon 28 37 27 15 57 23 0.061 Replication Centaurus 6
Mates et al. [50] 2011 Caucasian Colon 42 69 42 32 106 43 0.225 Replication Centaurus 7
Cui et al. [34] 2011 Asian Colon 1628 1007 155 2247 1190 147 0.501 Replication Illumina 8
Li et al. [22] 2011 Asian Colon 73 53 12 81 73 14 0.665 Replication Sequenom 7
Ho et al. [35] 2011 Asian Colon 343 420 129 376 405 109 0.997 Replication Sequenom 7
Song et al. [36] 2012 Asian Colon 399 232 10 732 272 33 0.214 Replication TaqMan 6
Lubbe et al. [51] 2012 Caucasian Colon 444 969 624 1394 3021 1636 0.993 Replication Allele-PCR 7
Garcia-Albeniz et 
al. [52]
2012 Caucasian Colon 90 233 118 538 1120 600 0.731 Replication TaqMan 8
Phipps et al. [53] 2012 Caucasian Colon 657 1526 884 574 1597 1112 0.988 Replication TaqMan 7
Kirac et al. [54] 2013 Caucasian Colon 63 143 96 172 291 131 0.705 Replication Illumina 8
Yang et al. [37] 2014 Asian Colon 342 298 65 891 752 159 0.985 Replication Allele-PCR 7
Kurlapska et al. [17] 2014 Caucasian Colon 54 93 65 716 1394 730 0.330 Replication Sequenom 7
(Continued )
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SNP Author Year Ethnicity Cancer 
type
Case Control HWE
(Control 
P value)
Study 
design
Genotyping 
method
Quality 
assessment
Zhang et al. [38] 2014 Asian Colon 400 277 51 1894 1170 212 0.858 Replication TaqMan 7
Hong et al. [19] 2015 Asian Colon 126 63 9 182 127 19 0.608 Replication Illumina 7
Baert-Desurmont et 
al. [55]
2016 Caucasian Colon 89 157 104 191 493 343 0.555 Replication SNaPshot 8
Abd EI-Fattah et al. 
[18]
2016 Caucasian Colon 20 35 22 11 15 10 0.319 Replication TaqMan 7
rs12953717 CC TC TT CC TC TT
Broderick et al.
-A group [12]
2007 Caucasian Colon 159 309 151 326 467 167 0.991 GWAS Illumina 8
-B group 2007 Caucasian Colon 1247 2204 973 1248 1898 722 0.994 Replication Allele-PCR 8
-C group 2007 Caucasian Colon 582 991 422 558 834 312 0.990 Replication Allele-PCR 8
-D group 2007 Caucasian Colon 277 468 198 106 168 67 0.976 Replication Allele-PCR 8
Middeldorp et al. [13] 2009 Caucasian Colon 301 493 201 482 643 215 0.982 Replication TaqMan 7
Curtin et al. [43] 2009 Caucasian Colon 314 530 226 332 521 188 0.509 Replication SNPlex 8
Thompson et al. [28] 2009 Mixed Colon 196 248 116 220 370 129 0.218 Replication TaqMan 8
Pittman et al. [56] 2009 Caucasian Colon 716 1261 555 859 1275 473 0.998 Replication Allele-PCR 8
Kupfer et al. [48] 2010 African Colon 401 327 67 525 388 72 0.979 Replication Sequenom 7
2010 Caucasian Colon 197 121 81 119 180 68 0.996 Replication Sequenom 7
Slattery et al. [46] 2010 Caucasian Colon 503 754 332 676 928 327 0.779 Replication Illumina 8
Ho et al. [35] 2011 Asian Colon 276 343 97 304 345 65 0.557 Replication Sequenom 7
Scollen et al. [56] 2011 Mixed Colon 710 1031 425 730 1083 437 0.326 Replication TaqMan 8
Zhang et al. [38] 2014 Asian Colon 418 263 47 1947 1135 194 0.096 Replication TaqMan 8
SNP: single nucleotide polymorphisms: HWE: Hardy-Weinberg equilibrium.
Table 2: Meta-analysis of the association between SMAD7 polymorphisms and colorectal cancer risk
SNP Comparison Subgroup Heterogeneity test Model PZ PE OR (95% CI)
I2 (%) PH
rs4464148 CC vs. TT+TC Overall 1.3 0.43 F <0.01 0.13 1.23(1.14–1.33)
Caucasian 12.3 0.33 F <0.01 1.22(1.13–1.32)
Asian 0 0.71 F 0.03 1.39(1.04–1.87)
CC+TC vs. TT Overall 73.8 0.00 R 0.07 0.51 1.10(0.99–1.22)
Caucasian 76.8 0.00 R 0.16 1.08(0.97–1.21)
Asian 0 0.41 F 0.02 1.36(1.05–1.75)
C vs. T Overall 66.2 0.00 R <0.01 0.36 1.12(1.04–1.19)
Caucasian 67.7 0.00 R 0.01 1.10(1.02–1.18)
Asian 66 0.09 F <0.01 1.35(1.12–1.63)
rs4939827 TT vs. CC+TC Overall 73.3 0.00 R <0.01 0.89 1.15(1.07–1.22)
Caucasian 61.2 0.00 R <0.01 1.19(1.12–1.26)
Asian 75.8 0.00 R 0.73 1.04(0.84–1.28)
TT+TC vs. CC Overall 71.8 0.00 R <0.01 0.14 1.13(1.07–1.20)
Caucasian 71.6 0.00 R <0.01 1.16(1.08–1.24)
Asian 74.0 0.00 R 0.31 1.07(0.94–1.23)
T vs. C Overall 79.6 0.00 R <0.01 0.45 1.11(1.06–1.16)
Caucasian 74.7 0.00 R <0.01 1.13(1.08–1.18)
Asian 56.9 0.00 R 0.33 1.07(0.94–1.21)
rs12952717 TT vs. CC+TC Overall 13.2 0.31 F <0.01 0.54 1.22(1.16–1.29)
(Continued )
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CI: 1.14–1.33; PZ < 0.01; PH = 0.43], while only a slight 
association was found for the dominant genetic model: CC 
+TC vs. TT (OR = 1.10; 95% CI: 0.99–1.22; PZ = 0.51; PH 
= 0.00). Subgroup analysis according to ethnicity showed 
that rs4464148 was significantly associated with CRC risk 
in both Caucasian and Asian populations (Table 2).
SMAD7 rs4939827 polymorphism
Similarly, we investigated the association between 
the SMAD7 rs4939827 polymorphism and CRC risk. 
Significant associations were found for both the recessive 
(Figure 2): TT vs. TC+CC (OR = 1.15; 95% CI: 1.07–1.22; 
PZ < 0.01; PH = 0.00) and the dominant genetic models: 
TT+ TC vs. CC (OR = 1.13; 95% CI: 1.07–1.20; PZ < 
0.01; PH = 0.00; Table 2). Subgroup analysis according 
to ethnicity showed that rs4939837 was significantly 
associated with CRC risk in the Caucasian population (27 
studies: 36,062 cases and 43,518 controls): TT vs. TC+CC 
(OR = 1.19; 95% CI: 1.12–1.26; PZ < 0.01; PH = 0.00 for 
heterogeneity), whereas it had no association with CRC 
risk among Asians (9 studies: 12,607 cases and 16,349 
controls): TT vs. TC+CC (OR = 1.04; 95% CI: 0.84–1.28; 
PZ = 0.73; PH = 0.00; Table 2).
SMAD7 rs12953717 polymorphism
In this meta-analysis, a strong association between 
the rs12953717 polymorphism and CRC risk was found 
for both the recessive: TT vs. CC+TC (OR = 1.22; 95% 
CI: 1.16–1.29; PZ < 0.01; PH = 0.31) and the dominant 
genetic models: TT+TC vs. CC (OR = 1.15; 95% CI: 1.08–
1.23; PZ < 0.01; PH = 0.02; Table 2). Further subgroup 
analysis based on ethnicity showed that rs12953717 was 
significantly associated with the risk of CRC in both 
Caucasians and Asians (Table 2).
Sensitivity analyses and publication bias
Our results suggested that the influence of individual 
data sets to the pooled ORs were not significant. Sensitivity 
analysis showed that no single study qualitatively altered 
the pooled ORs, providing evidence of the stability of the 
meta-analysis (Supplementary Figure S1). Funnel plots and 
Egger’s test were performed to assess publication bias. The 
results suggested that there was no publication bias for the 
comparison of rs4464148 allele C vs. allele T (t =0.96, PE = 
0.36), rs4939827 allele T vs. allele C (t =-0.76, PE = 0.45), 
or rs12953717 allele T vs. allele C (t =-0.19, PE = 0.85). 
The shape of Begg’s funnel plot did not reveal any obvious 
asymmetry (Supplementary Figure S2).
DISCUSSION
TGF-β signaling is essential for maintaining 
homeostasis, cell differentiation, and tumor suppression 
[3, 24, 25]. Increased production of TGF-β occurs 
in various tumor types, such as CRC [26]. As one of 
the key effectors of TGF-β signaling, perturbation of 
SMAD7 expression has been documented to influence 
CRC progression [7][27]. Though the functional role of 
the SMAD7 polymorphisms (rs4464148, rs4939827, and 
rs12953717) has not yet been interpreted, a number of 
published epidemiological studies have reported that these 
polymorphisms are correlated with the risk of developing 
multiple cancers [12, 28, 29]. However, other studies have 
reported that these polymorphisms are not associated with 
cancer development [17–20].
These conflicting studies based their conclusions on 
small numbers of samples and different detection methods. 
Therefore ameta-analysis from large-scale samples of 
all available studies is required to have a more accurate 
assessment as to whether the SMAD7 polymorphisms 
are related to risk of developing CRC. Our group has 
already used meta-analysis to systematically investigate 
the association between cancer risk and several SNPs 
involved in TGF-β signaling [30–32]. In this meta-
analysis, we found SMAD7 polymorphisms (rs4464148, 
rs4939827, and rs12953717) in the combined population 
were all significantly associated with CRC risk. Subgroup 
analysis according to ethnicity showed that rs4464148 
SNP Comparison Subgroup Heterogeneity test Model PZ PE OR (95% CI)
I2 (%) PH
Caucasian 0 0.87 F <0.01 1.25(1.18–1.32)
Asian 54.9 0.14 F 0.02 1.31(1.04–1.65)
TT+TC vs. CC Overall 51.3 0.02 R <0.01 0.66 1.15(1.08–1.23)
Caucasian 45.3 0.06 F <0.01 1.19(1.13–1.25)
Asian 0.0 0.54 F 0.082 1.12(0.99–1.28)
T vs. C Overall 51.5 0.02 R <0.01 0.85 1.13(1.09–1.19)
Caucasian 29.8 0.17 F <0.01 1.16(1.12–1.20)
Asian 19.6 0.27 F 0.02 1.13(1.02–1.25)
PH : P value of heterogeneity test; PZ : P value of Z test; PE : P value of Egger’s test. R: random-effects model. F: fixed-
effects model
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and rs12953717 were significantly associated with the 
risk of CRC among both Caucasian and Asian population, 
whereas rs4939827 seems to be a risk polymorphism for 
CRC only within a Caucasian population. There could 
be several possibilities to explain such a differential 
association. First, the difference in association may result 
from differences in socioeconomic environment, regional 
dietary habits, and race. Second, the number of rs4939827 
in Asian studies is still not as large as desired. In addition, 
the results from nine studies incorporated in this meta-
analysis conflict with each other [14, 19, 22, 33–38]. 
Therefore, more Asian studies are still needed to clearly 
evaluate the interactions of SMAD7 rs4939827 and CRC 
in this ethnic group.
One recent study [39] also assessed the associations 
between these three SNPs and CRC risk by meta-analysis; 
however, there were significant limitations. First, the 
number of studies included in their analysis was smaller 
than ours. Only 4 publications for rs4464148, which 
also lack relevant studies for Asian population, and 13 
publications for rs4939827 were included in their meta-
analysis, while 9 publications for rs4464148 and 25 
publications for rs4939827 were included in our work. 
Second, they only analyzed the relationship between 
SMAD7 polymorphisms and CRC risk under an allelic 
model, while we also analyzed under dominant and 
recessive models. Therefore, our updated meta-analysis at 
a much larger scale clearly provides a more credible and 
reliable assessment for the association between SMAD7 
polymorphisms and the risk to develop CRC.
Nonetheless, we also wish to acknowledge the 
limitations in our study. First, we stratified the studies by 
ethnic subtypes as Caucasian and Asian. However, we 
could not assess the association in the African population 
due to the insufficient number of African studies. Second, 
further subtle adjusted analysis could be carried out if 
more detailed individual information was available. 
Third, we only assessed the association of SMAD7 
polymorphisms with CRC risk, because there were not 
sufficient studies conducted on other cancers.
Figure 2: Forest plot of cancer risk associated with the SMAD7 polymorphisms in colorectal cancer studies with 
recessive genetic models. The squares and horizontal lines correspond to the study-specific odds ratio (OR) and 95% confidence interval 
(95% CI). The area of the squares reflects the weight (inverse of the variance). A. SMAD7 rs4464148; B. SMAD7 rs4939827; C. SMAD7 
rs12953717.
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To date, a large number of studies have focused 
on the relationship between SMAD7 polymorphisms and 
cancer. However, controversies remain as whether those 
polymorphisms indeed associate with increased cancer 
risks. Our large-scale meta-analysis demonstrated that the 
C allele of rs4464148, the T allele of rs4939827, and the 
T allele of rs12953717 were all significantly associated 
with the increased CRC risk, which may provide a basis 
for genetic testing in the development of CRC. Consistent 
with our findings, Noci et al. [40] recently showed that 
SMAD7 rs4939827 is also associated with cancer survival 
rate after therapy. Therefore, the identification of SMAD7 
polymorphisms may also benefit developing targeted 
and personalized therapy against CRC. However, more 
comparative studies are needed to evaluate interactions of 
SMAD7 polymorphisms and cancer risk in other specific 
cancer subtypes and ethnic subtypes
MATERIALS AND METHODS
Literature Search strategy
We searched for relevant case-control studies using 
the following words and terms: ‘‘SMAD7’’, “Mothers 
against decapentaplegic homolog 7”, “rs4464148”, 
“rs4939827”, “rs12953717”, ‘‘polymorphism’’ or 
‘‘variation’’, “susceptibility”, and “tumor” or ‘‘cancer’’ 
or ‘‘carcinoma’’ or ‘‘neoplasia’’ or “colorectal caner” or 
“CRC” in PubMed, the Web of Science, EBSCO, and 
Embase databases. There were no limitations on the 
language and year for the literature search. The last search 
was updated on June 30, 2016. References of the retrieved 
publications were also screened.
Inclusion criteria
Two authors independently screened titles and 
abstracts to identify relevant studies. Full-text articles of 
these studies were then carefully read to select eligible 
studies. Studies had to meet the following inclusion 
criteria: (a) were a case-control study, nested case-control 
or a cohort study; (b) evaluated the association between 
SMAD7 polymorphisms (“rs4464148”, “rs4939827”, and 
“rs12953717”) and CRC risk; (c) had available genotype 
frequencies both in cases and controls; (d) the genotype 
distribution in control groups was in Hardy-Weinberg 
equilibrium (HWE). (e) In cases of multiple studies with 
overlapping, redundant data published, only the most 
recent or complete study was included.
Qualitative assessment
Two authors independently conducted the quality 
assessment. The Newcastle–Ottawa Scale (NOS) was 
used to evaluate the study quality, which scored studies 
by the selection of the groups, the comparability of 
cases and controls, and the ascertainment of the 
exposure. We considered a study awarded 0-3, 4-6, 
or 7-9 as a low-, moderate-, or high-quality study, 
respectively [23].
Data extraction
Two authors independently selected the relevant 
articles and extracted the following data: first author’s 
name, publication date, ethnicity, cancer type, genotyping 
methods, number of cases and controls, and number of 
genotypes in case-control groups. In addition, P values 
according to the HWE in controls were extracted from the 
included studies.
Statistical analysis
Our meta-analysis was performed using Stata 
software (version 12.0; StataCorp LP, College Station, 
TX, USA). We first calculated the strength of the 
association between SMAD7 polymorphisms and CRC 
by odds ratio (OR) corresponding to 95% confidence 
interval (CI) for different genetic models. Then we 
stratified the studies by ethnic subtypes and examined 
the association between SMAD7 polymorphisms and 
the CRC risk (Table 2). A chi-square-based Q-statistic 
test [41] was performed to evaluate the between-study 
heterogeneity of the studies. PH < 0.05 was considered 
significant for heterogeneity. We also calculated the 
quantity I2 that represents the percentage of total 
variation across studies. As a guide, values of I2 less than 
25% were considered “low”, values about 50% were 
considered “moderate”, and values greater than 75% 
were considered “high”[42]. The fixed effects model was 
used when there was no heterogeneity of the results of 
studies; otherwise, the random-effects model was chosen. 
A pooled OR obtained by meta-analysis was used to give 
a more reasonable evaluation of the association. The 
significance of the pooled OR was determined by Z test 
(PZ ≤0.05 suggests a significant OR). Funnel plots were 
used to access publication bias by the method of Begg’s 
test and Egger’s test. A T test was performed to determine 
the significance of the asymmetry. An asymmetric plot 
suggested possible publication bias (PE ≥ 0.05 suggests 
no bias).
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